Authors of a single-center, real-world study in Turkey found that patients with diffuse large B-cell lymphoma (DLBCL) who received a rituximab biosimilar had similar overall survival as patients who received the originator. However, progression-free survival was longer in the originator group.
Zachary Epstein-Peterson, MD, discusses available treatment approaches for patients with mantle cell lymphoma who are transplant eligible or ineligible.
Dr. Reddy s Laboratories Ltd has successfully completed the full set of clinical studies of its proposed rituximab biosimilar candidate, DRL RI, for filing in highly regulated markets such as the United States, Europe and other regions.
Hyderabad: Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced that it has successfully completed the full set of clinical studies of its proposed rituximab biosimilar candidate, DRL RI, for filing in highly regulated markets such as the United States, Europe and other regions.